What are the signs of Neuroendocrine Tumors recurrence and how is it monitored

Signs of Neuroendocrine Tumor Recurrence and Monitoring

Neuroendocrine tumor (NET) recurrence can be challenging to detect because these tumors often grow slowly. Understanding what to watch for and how your medical team monitors for recurrence is important for your ongoing care.

Signs That May Suggest Recurrence

Physical Symptoms

Recurrence symptoms vary depending on where the tumor originally was and where it might return:

• Hormonal symptoms returning - If your original tumor produced hormones (like causing carcinoid syndrome with flushing, diarrhea, or heart palpitations), these symptoms coming back may signal recurrence
• New or worsening abdominal pain or bloating
• Unexplained weight loss
• Persistent fatigue or weakness
• Changes in bowel habits
• Nausea or loss of appetite

Biomarker Changes

Blood tests that measure tumor markers are often the first sign of recurrence, sometimes before imaging shows anything:

• Chromogranin A (CgA) - A protein released by neuroendocrine cells; rising levels may indicate recurrence
• NETest - A newer blood test measuring multiple genes that can detect recurrence with high accuracy (around 94% according to NCCN Guidelines)
• Functional tumor markers - If your tumor produced specific hormones (insulin, gastrin, VIP, etc.), rising levels of these substances may signal recurrence

---

How Recurrence Is Monitored

According to the NCCN Guidelines for Neuroendocrine Tumors, surveillance schedules depend on your tumor type, grade, and whether it was completely resected (surgically removed).

Standard Surveillance Timeline

First 2 years after treatment:

• Physical exams every 12-24 weeks
• Imaging studies (CT or MRI of abdomen/pelvis) every 12-24 weeks
• Chest CT as clinically indicated
• Biochemical markers (blood tests) if your tumor was functional

Years 2-10:

• Physical exams every 6-12 months
• Imaging every 6-12 months
• Continued biomarker monitoring as appropriate

After 10 years:

• Surveillance continues as clinically indicated, though frequency may decrease

Imaging Studies Used

SSTR-PET/CT or SSTR-PET/MRI (Somatostatin Receptor PET imaging)

• This is a specialized nuclear medicine scan that looks for cells with somatostatin receptors
• Uses tracers like 68Ga-DOTATATE to find NET cells throughout the body
• Particularly good at detecting small metastases (spread to distant sites)
• According to NCCN Guidelines, this is recommended for detecting recurrence

Multiphasic CT or MRI

• Standard imaging with contrast dye
• Performed in multiple phases (arterial and portal venous) to catch tumors at different stages
• Good for detecting larger lesions and assessing liver involvement

Chest CT

• Checks for spread to the lungs
• Performed as clinically indicated based on your tumor type

Biochemical Monitoring

For functional tumors (those that produce hormones), your doctor will monitor:

• Chromogranin A levels
• Specific hormone levels (depending on tumor type)
• The NETest - a blood-based test measuring multiple genes that can predict recurrence with high accuracy

According to NCCN Guidelines, the NETest has shown 94% accuracy in predicting neuroendocrine tumor recurrence and can identify residual disease after surgery.

---

Important Distinctions

What's NOT Routinely Used for Surveillance

• FDG-PET/CT - Not recommended for routine surveillance of well-differentiated NETs (though it may be used for poorly differentiated tumors)
• SSTR imaging is NOT recommended for routine follow-up after treatment, only when clinically indicated

---

Questions to Ask Your Healthcare Team

Since YOUR specific situation requires your doctor's evaluation, consider asking:

1. "What is my specific surveillance schedule based on my tumor type and grade?" - Schedules vary significantly based on whether you had a pancreatic NET, GI NET, lung NET, etc.

2. "Which biomarkers should we monitor, and how often should I have blood tests?" - This depends on whether your tumor was functional and your baseline marker levels.

3. "If my biomarkers start rising, what's the next step before we see anything on imaging?" - Understanding the plan helps you stay proactive.

4. "Should I be monitored with SSTR-PET imaging, or will standard CT/MRI be sufficient?" - This depends on your tumor's characteristics and somatostatin receptor status.

5. "What symptoms should I report immediately rather than waiting for my next scheduled visit?" - Knowing red flags helps you advocate for yourself.

6. "Are there any clinical trials I should consider if recurrence is detected?" - According to NCCN Guidelines, clinical trials are often preferred options for managing recurrent disease.

---

Why Early Detection Matters

According to the NCCN Guidelines for Patients with Neuroendocrine Tumors, catching recurrence early—especially through biomarker changes before imaging shows disease—allows your team to:

• Start treatment when tumor burden is lower
• Consider more treatment options
• Potentially achieve better outcomes

This is why regular monitoring with both blood tests AND imaging is so important, even when you feel well.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.